-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $325

Benzinga·11/02/2026 12:26:49
Listen to the news
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $290 to $325.